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1. Introduction 
ANCA – associated vasculitis (AAV) encompass Wegener granulomatosus (WG), Churg 
Strauss syndrome (CSS) and Microscopic Polyangiitis (MPA). Granuloma formation 
characterizes both WG and CSS, while necrotising inflammation of middle to small arteries, 
pauci-immune glomerulonephritis and production of ANCA typify all three of them. 
Common clinical and laboratory features point towards common pathogenetic mechanisms 
and thus therapeutic approach have evolved over the years from treatment of individual 
members of the group to unified treatment strategies. It is the presentation of the disease 
rather than a particular AAV that guides treatment decisions. Clinical subtypes of AAV 
according to the extend and the severity of the disease, have been proposed by the European 
Vasculitis Study (EUVAS) Group (Jayne & Rasmussen 1997) (Table 1): AAV can be 
presented as localized, early systemic, generalized, severe or refractory disease. This 
classification currently serves as the basis for the assignment of different treatment 
regimens. 
Forty years ago AAV was a rapidly fatal disease. One-year survival was estimated to be less 
than 20%, mainly due to pulmonary and/or renal failure and steroids-related infection 
(Hoffman et al. 1992). The introduction of oral cyclophosphamide (CyP) during the ‘70s 
radically changed the prognosis of AAV. Recent data from the EUVAS Group trials show 
that survival at 1-year is currently almost 90%. CyP in combination with prednisone remain 
today the cornerstone of treatment of AAV. However, several issues have emerged: a) there 
are still patients that either die early in the course of the disease or display progressive 
disease refractory to conventional treatment, b) relapses are frequent, affecting 
approximately 50% of patients with AAV during extended follow-up, c) the burden of drug-
related toxicity is high, as serious adverse events affect approximately 40% of the patients. 
In addition to glucocorticoids toxicity, CyP can acutely lead to cytopenias, hemorrhagic 
cystitis and infections along with late complications including gonadal insufficiency and 
infertility, myelodysplasias and bladder cancer.  
In an effort to minimize CyP toxicity as well as to find regimens that could replace CyP in 
cases of non-responding, refractory, or relapsing disease, several treatment options have 
been considered. During the last 20 years and despite the rarity of AAV, several multi-
center, multi-national randomized control trials (RCTs) were conducted largely due to the 
combined efforts of EUVAS Group and the VCRC (Vasculitis Clinical Research 
Consortium), which have altered our treatment practice as it will be discussed below. 
Treatment of AAV consists of an initial phase aiming at rapid induction of remission and a 
second phase where maintenance of remission is sought.  
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AAV Subtype Description 
Localized 
one system, 
typically the upper respiratory track in WG 
Early Systemic 
involvement of multiple sites but without 
impending renal or other vital organ failure 
Generalized 
impending vital organ failure or renal involvement 
with creatinine level below 5.6 mg/dL (500μmol/L) 
Severe 
vital organ failure, typically renal involvement with 
serum creatinine over 5.6 mg/dL (500μmol/L) 
Refractory progressive disease despite conventional treatment 
Table 1. Clinical Subtypes of AAV according to the extend and the severity of the disease 
2. Induction of remission 
The gold standard for induction of remission in most cases of AAV has been the 
combination of high dose prednisolone (1mg/kg/day with or without previous pulses 1g/d 
x 3d) with CyP either orally (2mg/kg/day) or intravenously (0.75 g/m2 every month for 6 
months) (Adu et al. 1997; Guillevin et al. 1997). In order to reduce the cumulative dose of 
drugs and thus adverse effects, current treatment strategies are differentiated according to 
the presentation of the disease (Table 1) and along with different schemes of CyP 
administration include several other medications such as rituximab, mycophenolate mofetil 
(MMF) and methotrexate (MTX).  
2.1 Generalized AAV  
Generalized AAV refers to patients who display imminent vital organ failure or renal 
involvement with creatinine level below 5.6 mg/dL (500μmol/L). 
In an earlier study including 47 patients with generalized AAV and renal involvement 
intravenous pulses of CyP (0.75 g/m2, monthly for 6 months) were equally effective in 
achieving remission as oral CyP. Moreover, fewer incidents of cytopenia and infections had 
been recorded in the pulse group (Haubitz & Schellong 1998).  
A randomized controlled trial by EUVAS, termed CYCLOPS, compared another scheme of 
pulse cyclophosphamide with daily oral cyclophosphamide for the induction of remission of 
AAV (De Groot et al. 2009). Patients with generalized AAV (n=149) and renal involvement 
received prednisolone plus either pulse cyclophosphamide (15 mg/kg every 2-3 weeks;  
n = 76) or daily oral cyclophosphamide (2 mg/kg per day; n=73). The efficacy of both 
regimens was similar in inducing remission. Lower cumulative dose of CyP was achieved in 
the pulse group, which displayed fewer episodes of leukopenia. It should be noted though 
that following pulse treatment there was a tendency towards a higher rate of relapse 
compared to oral treatment during the 9-month follow-up of the study.  
Although it is not clear whether there are significant differences regarding efficacy and 
safety between the 2 schemes of CyP pulses, EULAR recommendations endorse the 
following strategy (Mukhtyar et al. 2009): administration of 15mg/kg of CyP every 2 weeks 
for 3 pulses and then every 3 weeks for additional 3-6 pulses. According to the same set of 
recommendations prednisolone intake should start at 1mg/kg/day (or 60mg/day) for 1 
month, tapered to 15mg/day at 3 months and 7.5mg/day at 12 months.   
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Following the paradigm of lupus nephritis, MMF has been examined whether it can replace 
CyP for the induction of remission in AAV. In a study including 35 patients with AAV renal 
vasculitis with serum creatinine <5.6 mg/dL, 18 received MMF (2g/day) and 17 monthly 
pulses of CyP (0.75–1.0 g/m2) for 6 months (Hu et al. 2008). According to the study, 
complete remission was achieved in 78% in the MMF group compared to 47% in the CyP 
group. Whether MMF truly bears superiority towards CyP remains to be verified in large 
controlled trilas. MYCYC (http://clinicaltrials.gov/ct2/show/ NCT00414128 (2010)), a 
multi-center controlled trial by EUVAS comparing the efficacy of MMF and CyP has been 
initiated. Notably, MMF will be used at the increased dose of 3g/day.  
Rituximab, an anti-CD20 chimeric monoclonal antibody that effectively depletes B cells, has 
recently received much attention regarding its treatment potential in AAV. The number of 
activated B cells in AAV is associated with disease activity and the extend of organ 
involvement. Moreover, B cells generate ANCA-producing plasma cells. Studies in humans 
and animal models support the concept that ANCA have a central role in the pathogenesis 
and maintenance of AAV (Xiao et al. 2002) 
The efficacy of rituximab to induce remission in generalized AAV was examined in two 
RCTs. In RITUXVAS trial (Jones et al. 2010), 11 patients received pulses CyP plus 
glucocorticoids and 33 patients additionally received rituximab. The rituximab group 
received four infusions of rituximab 375 mg/m2 per week plus two infusions of intravenous 
cyclophosphamide 15 mg/kg. The cyclophosphamide group received between six and ten 
infusions of cyclophosphamide 15 mg/kg. Azathioprine was used as maintenance therapy 
in all patients. At 12 months, remission rates were comparable between the two groups (76% 
for rituximab and 82% for CyP group). Rituximab (375 mg/m2 per week for four weeks) was 
also compared with oral CyP (2 mg/ kg per day) in addition to glucocorticoids in the RAVE 
trial (Stone et al. 2010). At 6 months remission rates were 64% for the rituximab and 53% for 
the CyP group. These lower rates of remission compared to other studies were probably due 
to the aggressive tapering of corticosteroids employed.  
Overall, both studies show that rituximab therapy is not inferior to CyP (oral or pulses) 
treatment for the induction of remission in patients with generilized AAV. It should be noted, 
however, that adverse effects were also comparable between rituximab and CyP receivers an 
issue that has to be further addressed in studies with extended follow-up. Rituximab can thus 
replace CyP treatment especially in patients where CyP is contraindicated and could be the 
drug of choice in patients with childbearing potential. In spring of 2011, rituximab became the 
first drug to get an FDA approval for the treatment of AAV. 
2.2 Early systemic AAV 
Early systemic AAV refers to patients with involvement of multiple sites but without 
imminent renal or other vital organ failure.  
Following initial open label studies with promising results, the NORAM study (De Groot et 
al. 2005), a RCT initiated by EUVAS, evaluated the efficacy of MTX as a potentially less toxic 
than CyP alternative to induce remission in patients with early systemic AAV. In addition to 
corticosteroids, patients received either oral CyP (2 mg/Kg per day) or oral MTX (initial 
dose 15mg/week that was increased to 20-25mg/week) for 12 months. Patients’ follow-up 
lasted 18 months, and during the last 6 months all medications were stopped. At 12 months 
remission rates between the two groups were comparable (89.8% for MTX and 93.5% for 
oral CyP). Time to remission in overall was also comparable. However, some patients with 
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pulmonary involvement or relatively extensive disease in the MTX group had delayed onset 
of remission. In addition, at 18 months the relapse rate in the MTX group was 69.5%, which 
was significantly higher compared to that observed in the CyP group (46.5%). These high 
relapse rates in both treatment arms suggest that treatment of early systemic AAV should 
last beyond 1 year. The overall frequency of adverse events did not differ between the two 
groups. Leukopenia was prevalent with the use of CyP as was liver dysfunction with the 
use of MTX. In view of the results of the NORAM study, EULAR recommend MTX as an 
alternative to CyP for remission induction in non-organ-threatening or non-life threatening 
AAV.  
2.3 Severe AAV 
Severe AAV refers to patients with vital organ failure, typically renal involvement with 
serum creatinine over 5.6 mg/dL (500μmol/L).  
Patients with life- and/or vital organ threatening manifestations, such as diffuse alveolar 
hemorrhage (DAH), severe rapidly progressive glomerulonephritis (serum creatinine >5.6 
mg/dL), glomerulonephritis with double serum positivity for MPO-ANCA and anti-
glomerular basement membrane antibodies (Rutgers et al. 2005), require urgent, aggressive 
treatment. Supportive measures such as blood transfusion and mechanical ventilation or 
hemodialysis are frequently required. 
In a EUVAS trial called MEPEX (Jayne et al. 2007) the effectiveness of plasma exchange was 
evaluated in patients with severe AAV involving acute renal failure. All 137 patients 
received oral CyP and prednisolone. One group was assigned to additionally receive three 
infusions of 1g methylprednisolone pulse therapy (n=67) and a second to receive seven 
courses of plasma exchanges (n=70). At 3 months, 69% of patients who received plasma 
exchanges were alive and dialysis independent compared to the significantly lower 49% of 
patients treated with methylprednisolone pulses.  
The usefulness of plasma exchange in patients already on dialysis at the time of diagnosis 
has also been suggested (de Lind et al. 2007). Intravenous pulses methylprednisolone as 
adjunctive therapy in patients with severe tubular atrophy and <18% normal glomeruli 
increased the chance of therapy-related death over the chance of dialysis independence. The 
same was true for the group receiving plasma exchange only when the proportion of normal 
glomeruli reached a value of <2%.  
Although there are no RCT available, plasma exchanges appear to be warranted in patients 
with DAH. In a retrospective review of 20 patients with DAH that were presented at a 
single institute and were treated with plasma exchanges in addition to intravenous 
methylprednisolone with or without CyP, resolution of lung hemorrhage was achieved in 
all 20 patients after an average number of 6.4 treatments. Historical review of 11 patients 
hospitalized at the same centre and did not receive plasma exchanges revealed 3 deaths. 
(Klemmer Am J Kid Dis 2003).  
2.4 Other treatments 
Anti-Tumor Necrosis Factor (anti-TNF) regimens have been considered as an alternative to 
current treatment for over a decade. Based on the beneficial effects of TNF blockade in other 
chronic inflammatory disorders and the fact that several lines of evidence implicate TNF in 
the pathogenesis of AAV in humans and animal models of the disease, several small pilot 
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studies evaluated the therapeutic potential of infliximab revealing promising results. 
However, data derived from subsequent studies were conflicting and could not corroborate 
any additional benefit from the use of infliximab in patients with AAV (Booth et al. 2004; 
Josselin et al. 2008; Morgan et al. 2010). It should be noted that there is no RCT for infliximab 
in AAV. On the contrary, the effect of entanercept, another anti-TNF agent, was examined in 
a large RCT (WGET) with patients suffering from WG (Wegener's G.E.T.W. 2005). In WGET, 
etanercept was used as an additional therapy to standard treatment for the induction and 
maintenance of remission in 180 patients with WG. At 27 months, remission rates and time-
to-remission, were not significantly different between the two groups. It should be 
emphasized that six patients in the etanercept group developed solid cancers compared to 
no such malignancies in the control group (Stone et al. 2006). Hence, etanercept is 
considered ineffective and potentially hazardous when added to standard therapy for 
induction and maintenance of remission in WG. The overall experience with anti-TNF drugs 
in AAV is either negative or inconclusive. Skepticism has replaced initial enthusiasm and 
currently the use of TNF blockade in patients with AAV appears remote.  
 
 
Drug Dosage Comments 
Prednisolone 60 mg/day for 1 month 
tapered to 15 mg/day at 3 
months 
Use IV methylprednisolone 500-1,000 




15 mg/Kg 2-weekly for 3 
pulses, then 3-weekly for 3-6 
pulses 
Oral cyclophosphamide (2 
mg/Kg/day) might be used adjusted 
to keep WBC >3,000/µL 
Methotrexate Starting dose 15 mg/week, 
increased to 20-25 mg/week 
at 2 months 
Use in non critical organ manifestations 
(normal serum creatinine) 
Rituximab IV 375 mg/m2/week for 4 
pulses 
Use in intolerance to CyP and in young 




2 g/day In patients with moderate renal 
involvement who cannot take 
cyclophosphamide 
Plasmapheresis  Use in critical organ manifestations 
(serum creatinine >5.6 mg/dL, lung 
hemorrhage) 
Table 2. Induction of remission in ANCA-associated vasculitis 
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Since ANCA may have a central role in the pathogenesis of AAV, the idea to target 
autoreactive T cells that drive the production of ANCA excreeting-plasma cells appears to 
be a logical treatment approach. Abatacept, a CTLA4—Ig molecule, blocks the co-
stimulatory talk between T and B cells and has been proven efficacious in the treatment of 
rheumatoid arthritis. A RCT to evaluate relapse rate over a 24 month period in patients 
treated for 12 months with abatacept in addition to standard treatment (MTX plus 
prednisone) had been initiated but unfortunately was recently terminated due to slow 
recruitment (ABAVAS Study NCT00482066).  
Recent data generated increased interest towards the role of the complement pathway in the 
pathogenesis of AAV, which appears to have an essential role on how ANCA can damage 
the vascular wall. Eculizumab is a monoclonal antibody that blocks the activation of C5, a 
central component of the complement cascade. Blockade of C5 activation was shown to have 
substantial therapeutic effect in animal models of AAV. A similar approach to treat patients 
with AAV will be evaluated in a pilot study with 10 patients receiving eculizumab in 
addition to standard treatment (study NCT01275287).  
In anticipation of novel treatments, drugs currently used to induce remission in AAV are 
summarized in Table 2 and include corticosteroids, CyP, MTX, MMF, Rituximab and 
plasmapheresis.     
3. Maintenance of remission 
The majority of patients with AAV can achieve remission within the first 6 months of 
treatment. However, if no other care is undertaken over half of the patients may have a 
relapse within the first 2 years following remission (De Groot et al. 2005). Relapses in AAV 
were associated with subsequent progression to end-stage renal disease (Hogan et al. 2005). 
Moreover, the number of relapses for an individual patient was a strong predictor of 
damage during follow-up, as measured by the Vasculitis Damage Index (Koldingsnes & 
Nossent 2002). Therefore maintenance, once remission is achieved, is essential for the long 
term outcome of patients with AAV. 
CyP as oral (1.5mg/kg per day) or infusion regimen (0.75/m2, effusion every 3 months) was 
initially the standard regimen to maintain remission (Hoffman et al. 1992). Because of the 
serious adverse events related to long term exposure to CyP less toxic drugs have been 
proposed such as azathioprine, methotrexate, leflunomide or MMF 
The CYCAZAREM study by EUVAS randomly assigned 144 patients with AAV (who 
achieved remission with oral CyP and prednisolone) to receive either azathioprine (2 mg/kg 
per day; n = 71) or CyP (1.5 mg/kg per day; n = 73) (Jayne et al. 2003). Both treatment 
groups continued to receive prednisolone (7.5 mg per day). At 18 months of follow-up, 
relapses had occurred in 15.5% and 13.7% of patients in the azathioprine and CyP group, 
respectively, suggesting that azathioprine is as effective as CyP for maintaining remission in 
AAV. Adverse events were comparable between the two treatment groups. 
In a RCT by the French Vasculitis Study Group, 126 patients with WG or MPA following 
induction therapy, were randomly assigned to receive either oral azathioprine (2 mg/kg per 
day; n = 63) or methotrexate (0.3 mg/kg per week, progressively increased to 25 mg per 
week; n = 63) for 12 months. No significant difference was found between the two groups in 
terms of relapse-free survival and toxicity at a follow-up period of 29 ± 13 months (Pagnoux 
et al. 2008).  
In another RCT, 54 patients with WG (who achieved remission after treatment with 
cyclophosphamide and prednisolone) were randomly assigned oral leflunomide (30 mg per 
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day) or oral methotrexate (starting with 7.5 mg per week and reaching 20 mg per week after 
8 weeks) for 2 years (Metzler et al. 2007). Leflunomide was more effective in preventing 
relapses than oral methotrexate (6 versus 13 relapses, respectively), but was associated with 
a higher rate of adverse events. However, this study was underpowered; it was initially 
designed for 154 patients but only 54 were enrolled. 
The potential benefit of MMF treatment for maintenance of remission in AAV has been 
demonstrated in preliminary uncontrolled studies (Silva et al. 2010). On the basis of these 
studies, an RCT by EUVAS, termed IMPROVE, comparing MMF with azathioprine for 
maintenance of remission in renal vasculitis, has been carried out (Hiemstra et al. 2010). 
Among 156 patients treated either with AZA (starting at 2 mg/kg/d) or MMF (starting at 
2000 mg/d) following induction of remission with CyP and prednisolone, patients on MMF 
experienced more relapses compared to AZA group. 
Some observational studies provide preliminary data regarding the efficacy of other 
regimens to maintain remission in patients with AAV. Rituximab appears to be beneficial 
(Stasi et al. 2006; Rhee et al. 2010). A large RCT currently evaluates the efficacy of rituximab 
in comparison to AZA (MAINRITSAN , Study NCT00748644).  On the contrary, addition of 
intravenous immunoglobulin (IVIg) to standard maintenance treatment (AZA plus 
prednisone) does not prevent relapses (Fortin et al. 2009). 
In overall, treatment with low-dose prednisolone plus AZA (2 mg/Kg/day until 12 months 
then 1.5 mg/Kg/day) (Jayne et al. 2003; Pagnoux et al. 2008), or MTX (20-25 mg/week) 
(Pagnoux et al. 2008) is currently the preferred approach for maintenance of remission in 
AAV. The duration of maintenance is not known but should be >24 months (Lapraik et al. 
2007) (Table 3).  
 
Drug Dosage Comments 
Prednisolone Starting from 15 
mg/day at 3 months 
tapered to 7.5 mg/day 
at 12 months 
Alternate-day schemes have also been 
applied to minimize side effects. Should 
probably be avoided in generalized or 
severe forms of the disease 
Cyclophosphamide 
IV pulse 
0.75 mg/m2 every 3 
months  
Oral cyclophosphamide (1.5 
mg/Kg/day) might be used adjusted to 
keep WBC >3,000/µL in patients who 
experience frequent relapses 
Azathioprine 2 mg/kg/day for 12 
months then 1.5 
mg/kg/day 
Currently the gold standard for 
maintenance of remission 
Methotrexate  Starting dose 0.3/kg 
per week, increased to 
25 mg per week  
At high doses is a good alternative to 
Azathioprine 
Rituximab IV 375 mg/m2 every 6 
months 
Waits to be compared with 
Azathiprione. Should be considered in 
patients where AZA or MTX is either 
contraindicated or ineffective. 
Maintenance treatment should last > 24 months 
Table 3. Maintenance of remission in ANCA-associated vasculitis  
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Symptoms and signs of apparent AAV relapse, especially in patients on 
immunosuppression, should be differentiated from infections and malignancies. Relapse 
can be treated with oral or IV pulses of CyP plus prednisolone (60 mg/day) (Wegener's 
G.E.T.W. 2005). Patients intolerant to CyP can receive MMF (Stassen et al. 2007) or 
rituximab. IVIg (added to maintenance treatment) can achieve remission (Martinez et al. 
2008) and it is particularly useful until infection is ruled out.   
5. Refractory disease 
Refractory disease refers to patients who experience progressive disease despite 
conventional treatment. 
Patients with refractory disease should be treated in specialized centers. Rituximab has been 
successful in CyP-refractory disease in observational studies (Smith et al. 2006; Keogh et al. 
2006; Jones et al. 2009; Keogh et al. 2005). Deoxyspergualin (0.5 mg/Kg/day subcutaneously 
in 6 cycles of 21 days with 7-day intervals), an antiproliferative agent licensed in Japan for 
acute renal transplant rejection,  showed promise in phase II study (Flossmann et al. 2009). 
Infliximab was beneficial in refractory disease in observational studies (Josselin et al. 2008) 
but when added to standard induction treatment did not make any difference (Morgan et al. 
2010). 
6. Special issues 
6.1 End stage renal disease (ESRD) and renal transplantation  
Relapse of ANCA-associated vasculitis is significantly less frequent (0.08 episodes/person-
year) in ESRD patients compared with patients with preserved renal function (0.16-0.20 
episodes/person-year), but infection, an important cause of death is almost double in 
frequency in ESRD (Lionaki et al. 2009). Therefore, immunosuppression in patients with 
ESRD may be limited to patients with active vasculitis.  
Patients with ESRD can receive renal transplants. The overall survival of renal transplants is 
90% at 5 years (Gera et al. 2007), and 70% at 10 years (Little et al. 2009). In one study, risk 
factors for renal transplant rejection was transplantation <12 months postvasculitis 
remission (Little et al. 2009). Therefore, renal transplantation should be considered in 
patients with ESRD with sustained remission of vasculitis.  
6.2 Subglottic stenosis  
Patients with active disease receive aggressive treatment with prednisolone and CyP, and 
tracheostomy, if needed. Rituximab may also be used in case of CyP inadequate response. In 
inactive disease, intralesional costicosteroid with dilatation is generally effective 
(Hernandez-Rodriguez et al. 2010). 
6.3 Orbital mass 








CyP dose should be adjusted for renal function and age.  
There should be vigilance for side effects of drugs used (CyP, rituximab, MTX, IVIg, 
plasmapheresis). Patients should be checked for tuberculosis with chest x-rays and PPD skin 
test, and patients with latent tuberculosis should receive prophylaxis with isoniazid plus 
vitamin B6. Patients on IV pulse CyP, receive antiemetic drug (ondesarton) immediately 
prior to and 8 hours after the CyP pulse. On the day of IV CyP pulse, patients receive oral or 
IV hydration with 2-3 liters of fluid. They also receive IV 2-mercaptoethanesulfonate 
(mesna) (20% of CyP dose) immediately before and at 2, 4 and 8 hours after the CyP pulse to 
reduce irritation of urinary bladder. The dose of next IV CyP pulse is adjusted to keep nadir 
WBC (12-14 days after the IV pulse) >3,000/µL. The rate of leucopenia, infections, and 
gonadal toxicity is reduced in the IV pulse CyP compared to oral CyP regimen (De Groot et 
al. 2009; Haubitz & Schellong 1998). Oral mesna is also beneficial for patients on oral CyP. 
According to a recent study ever-tobacco smoking and previous episode of hemorrhagic 
cystitis were strong predictors for the development of cancer in the urinary tract. Thus 
patients with these characteristics need close surveillance. 
All patients receiving CyP are advised to take prophylaxis against Pneumocystis jiroveci 
with trimethoprime/sulphamethoxazole (800/160 mg thrice weekly). This may also prevent 
relapses in patients with respiratory involvement (Zycinska et al. 2009).  
Gonadal failure is a common side effect in patients treated with CyP, where the risk 
increases in parallel with the increase of the cumulative dose received. No standard care 
to preserve gonadal function has been proposed for patients with AAV under CyP. 
Similar issues encountered in patients with systemic lupus erythematosus (SLE) have 
been addressed. For women with SLE two protocols exist: administration of leuprolide 
acetate with or without transdermal estrogen and depo-progesterone for contraception. 
Leuprolide should be administered 10-14 days prior to each CyP infusion. In men with 
SLE, administration of intramuscular monthly injections of testosterone has been 
proposed. Analogous approaches should probably be established for young patients with 
AAV at risk. 
Patients on immunosuppression should not be vaccinated with live attenuated vaccines. 
They can and should be vaccinated with dead pathogens. Patients with WG exhibit 
adequate antibody (Holvast et al. 2009) and cell-mediated (Holvast ARD2010) immune 
response to influenza vaccines (Holvast et al. 2010). 
7. Conclusion 
The treatment of ANCA-associated vasculitis (AAV) has evolved over the years from 
treatment of individual members of the group i.e Wegener granulomatosis(WG), Churg-
Strauss syndrome (CSS), microscopic polyangiitis (MPA), to unified treatment. For years, 
treatment of WG was corticosteroids plus oral cyclophosphamide (CyP), which was 
effective but had a high frequency of severe adverse effects (Hoffman AIM1992).  To reduce 
the adverse effects of CyP, notably, bone marrow suppression and infections, hemorrhagic 
cystitis, gonadal toxicity, and tumors, other regimens were sought. So, intense 
immunosuppression with CyP is used only for induction of remission, and then remission is 
maintained with drugs with fewer side effects, such as azathioprine (AZA) and 
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methotrexate (MTX). In addition, the regimen for the induction of remission is 
individualized according to disease severity.  
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